Heidi A Tissenbaum from 32 Oak Hill Rd, Wayland, MA 01778, age 61, Phone: 508 788-7208

Age-1 Polypeptides And Related Molecules And Methods
view source
US Patent:

7094889, Aug 22, 2006
Filed:

Aug 7, 1997
Appl. No.:

08/908453
Inventors:

Gary Ruvkun - Newton MA, US
Jason Morris - New York NY, US
Heidi Tissenbaum - Belmont MA, US
Assignee:

The General Hospital Corporation - Boston MA
International Classification:

C07H 21/04
C12N 9/12
C12N 15/00
C12N 15/09
C12N 15/63
C12N 15/70
C12N 15/74
C12N 5/00
C12N 5/02
C12Q 1/68
G01N 33/53
US Classification:

536 235, 435194, 4353201, 435325, 435 6, 435 71, 435 701
Abstract:

Disclosed are substantially pure AGE-1 polypeptides and purified DNAs, vectors, and cells encoding those polypeptides. Also disclosed are methods for determining longevity and isolating antagonists using the AGE-1 sequence.

Therapeutic And Diagnostic Tools For Impaired Glucose Tolerance Conditions
view source
US Patent:

7414169, Aug 19, 2008
Filed:

Apr 27, 2001
Appl. No.:

09/844353
Inventors:

Gary Ruvkun - Newton MA, US
Koutarou Kimura - Boston MA, US
Garth Patterson - Charlestown MA, US
Scott Ogg - Newton MA, US
Suzanne Paradis - Somerville MA, US
Heidi Tissenbaum - Belmont MA, US
Jason Morris - New York NY, US
Allison Koweek - Somerville MA, US
Assignee:

The General Hospital Corporation - Boston MA
International Classification:

G01N 33/00
A01K 67/00
A01N 37/18
C12P 21/06
C12N 15/63
C12N 5/00
US Classification:

800 3, 800 8, 800 9, 435 691, 4353201, 435325, 435455, 514 2
Abstract:

Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.

Methods Of Identifying Longevity Modulators And Therapeutic Methods Of Use Thereof
view source
US Patent:

7858327, Dec 28, 2010
Filed:

Dec 23, 2003
Appl. No.:

10/746910
Inventors:

Heidi A. Tissenbaum - Wayland MA, US
Seung Wook Oh - Westborough MA, US
Assignee:

University of Massachusetts - Boston MA
International Classification:

A61K 49/00
G01N 33/53
G01N 33/567
US Classification:

435 72, 424 92
Abstract:

The present invention is based at least in part on the discovery of a role for the JNK signaling pathway in longevity. In particular, the present inventors have shown that modulation of the c-jun N-terminal kinase (JNK) signaling pathway in an organism, optionally in combination with modulation of the insulin receptor (IR) signaling pathway, can enhance longevity in an organism. Accordingly, the present invention features methods of identifying modulators of longevity in assays featuring organisms and/or cells having either a functional or deregulated JNK signaling pathway and, optionally, a functional or deregulated IR signaling pathway. Also featured is an in vitro method of identifying an agent capable of enhancing longevity featuring an assay composition having a JNK signaling pathway molecule and insulin signaling pathway molecule. Further featured are therapeutic methods for the use of JNK signaling pathway modulators to enhance longevity.

Neurotransmitter Signaling Can Regulate Life Span In
view source
US Patent:

7914998, Mar 29, 2011
Filed:

Mar 29, 2004
Appl. No.:

10/813324
Inventors:

Heidi A. Tissenbaum - Wayland MA, US
Christian Grove - Worcester MA, US
Nenad Svrzikapa - Somerville MA, US
Seung Wook Oh - Westborough MA, US
Melissa Grabowski - Worcester MA, US
Yamei Wang - Worcester MA, US
Assignee:

University of Massachusetts - Boston MA
International Classification:

G01N 33/53
US Classification:

435 71, 435 722, 435 721
Abstract:

The present invention features methods of identifying modulators of longevity. Also featured are organisms, cell systems and compositions for performing those methods. Further featured are therapeutic methods for the use of modulators identified according to said methodologies.

Methods Of Identifying Longevity Modulators And Therapeutic Methods Of Use Thereof
view source
US Patent:

7932049, Apr 26, 2011
Filed:

Mar 8, 2006
Appl. No.:

11/372469
Inventors:

Heidi A. Tissenbaum - Wayland MA, US
Seung Wook Oh - Lewisville TX, US
Assignee:

University of Massachusetts - Boston MA
International Classification:

C12Q 1/48
G01N 33/53
US Classification:

435 15, 435 71
Abstract:

The present invention is based at least in part on the discovery of a role for the JNK signaling pathway in longevity. In particular, the present inventors have shown that overexpression of c-jun N-terminal kinase 1 (jnk-1) extends lifespan and that said extended lifespan is associated with DAF-16 phosphorylation by JNK-1 and the consequent DAF-16 localization to the nucleus. Accordingly, the present invention features methods of identifying modulators of longevity in assays featuring organisms and/or cells having a JNK signaling pathway and, optionally, an IR signaling pathway. Also featured is an in vitro method of identifying an agent capable of enhancing longevity featuring an assay composition having a JNK signaling pathway molecule and insulin signaling pathway molecule. Further featured are therapeutic methods for the use of JNK signaling pathway modulators to enhance longevity, to prevent or reduce obesity and to prevent or treat type II diabetes.

Methods Of Identifying Modulators Of The Pp2A B56 Beta Regulatory Subunit
view source
US Patent:

20110286930, Nov 24, 2011
Filed:

Sep 24, 2009
Appl. No.:

13/120613
Inventors:

Heidi A. Tissenbaum - Wayland MA, US
Srivatsan Padmanabhan - Shrewsbury MA, US
Arnab Mukhopadhyay - New Delhi, IN
Sri Devi Narasimhan - Allston MA, US
Assignee:

UNIVERSITY OF MASSACHUSETTS - Boston MA
International Classification:

A61K 49/00
C12Q 1/02
A61P 3/04
A61P 35/00
A61K 31/713
A61P 3/10
US Classification:

424 92, 514 44 A, 435 613
Abstract:

The present invention is based at least in part on the discovery that the PP2A B56 regulatory subunit plays a role in regulating insulin signaling by directly regulating phosphorylation of AKT-I. Accordingly, the present invention features methods of identifying modulators of the PP2A B56 regulatory subunit in assays featuring organisms and/or cells. Further featured are therapeutic methods for the use of PP2A B56 regulatory subunit modulators to enhance longevity, to prevent or treat cancer, to prevent or reduce obesity and to prevent or treat type II diabetes.

Therapeutic And Diagnostic Tools For Impaired Glucose Tolerance Conditions
view source
US Patent:

62251201, May 1, 2001
Filed:

May 15, 1997
Appl. No.:

8/857076
Inventors:

Gary Ruvkun - Newton MA
Koutarou Kimura - Boston MA
Garth Patterson - Charlestown MA
Scott Ogg - Newton MA
Suzanne Paradis - Somerville MA
Heidi Tissenbaum - Belmont MA
Jason Morris - New York NY
Allison Koweek - Somerville MA
Assignee:

The General Hospital Corporation - Boston MA
International Classification:

C12N 500
C12N 1500
A01K 6700
US Classification:

435375
Abstract:

Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.

Heidi A Tissenbaum